Outcomes of Focal Ablation for Prostate Cancer

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Jul 25, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called focal ablation for men with localized prostate cancer. Focal ablation is a way to target and destroy cancer cells in the prostate while trying to spare healthy tissue. The goal of the study is to see how well this treatment works in controlling the cancer and to understand how it affects the quality of life for patients afterward. Researchers are looking for men aged 18 to 90 who have been diagnosed with prostate cancer through a biopsy and have no evidence of the cancer spreading beyond the prostate.

If you or someone you know is interested in participating, it’s important to know that candidates must be able to understand and agree to the study by signing a consent form. Participants will receive the ablative therapy and will be monitored for their health and quality of life after the treatment. However, individuals with certain health issues, such as infections or anatomical problems that prevent the procedure, will not be eligible. This trial aims to provide valuable information on the safety and effectiveness of this approach to treating localized prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
• • Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease
• • Age 18-90 years.
• • Life expectancy \> 1 year
• • Ability to understand and the willingness to sign a written informed consent.
• Exclusion Criteria:
• • Anatomic abnormalities that do not allow for focal ablation
• • Evidence of non-organ confined disease that is not feasible for ablation
• • Has active urinary traction infection